ATAI Stock Overview
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Atai Life Sciences N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.07 |
| 52 Week High | US$2.85 |
| 52 Week Low | US$1.03 |
| Beta | 0.98 |
| 1 Month Change | 23.95% |
| 3 Month Change | 16.95% |
| 1 Year Change | 0.98% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -89.36% |
Recent News & Updates
Recent updates
Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?
Mar 02
atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug
Oct 12Atai Life Sciences: Decentralized Drug Discovery Platform
Oct 06ATAI Life Sciences GAAP EPS of -$0.24 misses by $0.01
Aug 15We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely
Aug 07Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics Developer
Jul 07atai Life Sciences company Kures Therapeutics appoints Dr. Chad Beyer as CEO
Jun 30Atai Life Sciences N.V.: A First Take
Jun 02Atai Life Sciences And The Future Of Psychedelics For Mental Health
May 27We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely
Apr 22Shareholder Returns
| ATAI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -14.8% | -2.2% | -3.7% |
| 1Y | 1.0% | 11.6% | 20.5% |
Return vs Industry: ATAI underperformed the US Pharmaceuticals industry which returned 11.3% over the past year.
Return vs Market: ATAI underperformed the US Market which returned 20.9% over the past year.
Price Volatility
| ATAI volatility | |
|---|---|
| ATAI Average Weekly Movement | 14.0% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ATAI's share price has been volatile over the past 3 months.
Volatility Over Time: ATAI's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 83 | Florian Brand | www.atai.life |
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology.
Atai Life Sciences N.V. Fundamentals Summary
| ATAI fundamental statistics | |
|---|---|
| Market cap | US$356.96m |
| Earnings (TTM) | -US$40.22m |
| Revenue (TTM) | US$314.00k |
1,095x
P/S Ratio-8.5x
P/E RatioIs ATAI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATAI income statement (TTM) | |
|---|---|
| Revenue | US$314.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$314.00k |
| Other Expenses | US$40.54m |
| Earnings | -US$40.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 100.00% |
| Net Profit Margin | -12,810.19% |
| Debt/Equity Ratio | 8.3% |
How did ATAI perform over the long term?
See historical performance and comparison